Roivant Sciences

Roivant Sciences Announces Pricing of Upsized Public Offering of Common Shares

Retrieved on: 
Friday, February 3, 2023
Telephone, EDGAR, Attention, Lexington Avenue, Goldman Sachs, State Street, S-3, Sale, 4th floor, Capital market, Roivant Sciences, Form, Park Avenue, Prospectus, Security (finance)

BASEL, Switzerland and LONDON and NEW YORK and BOSTON, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Roivant Sciences (Nasdaq: ROIV) today announced the pricing of an upsized underwritten public offering of 26,666,666 of its common shares at a price to the public of $7.50 per share.

Key Points: 
  • BASEL, Switzerland and LONDON and NEW YORK and BOSTON, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Roivant Sciences (Nasdaq: ROIV) today announced the pricing of an upsized underwritten public offering of 26,666,666 of its common shares at a price to the public of $7.50 per share.
  • All of the common shares to be sold in the offering are to be sold by Roivant.
  • The gross proceeds to Roivant from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be $200 million.
  • In addition, Roivant has granted the underwriters a 30-day option to purchase up to an additional 3,999,999 common shares on the same terms and conditions.

Roivant Sciences Announces Proposed Public Offering of Common Shares

Retrieved on: 
Wednesday, February 1, 2023
Telephone, EDGAR, Attention, Lexington Avenue, Goldman Sachs, State Street, S-3, Sale, 4th floor, Capital market, Roivant Sciences, Form, Park Avenue, Prospectus, Financial adviser

BASEL, Switzerland and LONDON and NEW YORK and BOSTON, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Roivant Sciences Ltd. (Nasdaq: ROIV) announced today that it has commenced an underwritten public offering of $150 million of common shares.

Key Points: 
  • BASEL, Switzerland and LONDON and NEW YORK and BOSTON, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Roivant Sciences Ltd. (Nasdaq: ROIV) announced today that it has commenced an underwritten public offering of $150 million of common shares.
  • In addition, Roivant expects to grant the underwriters a 30-day option to purchase up to an additional $22.5 million of common shares.
  • All of the common shares are being offered by Roivant.
  • The proposed offering is subject to market conditions and other factors, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Roivant to Report Financial Results for the Third Quarter Ended December 31, 2022 on Monday, February 13, 2023

Retrieved on: 
Monday, January 30, 2023
Conference, Webcast, Roivant Sciences

ET

Key Points: 
  • ET
    BASEL, Switzerland and LONDON and NEW YORK and BOSTON, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Roivant Sciences (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m.
  • ET on Monday, February 13, 2023, to report its financial results for the third quarter ended December 31, 2022 and provide a corporate update.
  • The presentation and webcast details will also be available under “Events & Presentations” in the Investors section of the Roivant website at https://investor.roivant.com/news-events/events.
  • ET
    A live webcast of each presentation will be available under “Events & Presentations” in the Investors section of the Roivant website.

Myovant Sciences Announces Corporate Updates and Financial Results for Third Fiscal Quarter 2022

Retrieved on: 
Thursday, January 26, 2023
Research, Prostate cancer, Food, Gonadotropin-releasing hormone, USPI, Scott Richter, Endometriosis, Hart–Scott–Rodino Antitrust Improvements Act, History, Sale, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, FDA, SG, Roivant Sciences, SPIRIT, ORGOVYX, New Drug Application, EMA, Woman, RWS, Shanda, United Kingdom, Type 2, TRX, Richter, Pain, Safety, PDUFA, R, NYSE, Type, Risk, European Medicines Agency, Calendar, Patient, Growth, Uterine fibroid, German–Soviet Commercial Agreement (1940), Leuprorelin, Video game, Fine chemical, Credit, Security (finance), Pharmaceutical industry, Health insurance, Medical imaging, Airline, Takeda, Accord, Pfizer

Third fiscal quarter 2022 net product revenues for ORGOVYX in the U.S. were $48.7 million, reflecting 12% sequential growth compared to the second fiscal quarter 2022.

Key Points: 
  • Third fiscal quarter 2022 net product revenues for ORGOVYX in the U.S. were $48.7 million, reflecting 12% sequential growth compared to the second fiscal quarter 2022.
  • Approximately 4,000 new patients started treatment with ORGOVYX in the third fiscal quarter of 2022, reaching approximately 26,000 cumulative patients since launch.
  • In December 2022, Myovant completed a New Drug Submission to Health Canada seeking marketing approval for ORGOVYX for advanced prostate cancer.
  • Third fiscal quarter 2022 net product revenues for MYFEMBREE in the U.S. were $10.5 million, reflecting 64% sequential growth compared to second fiscal quarter 2022.

Affimed Reports on Corporate Progress and Provides Regulatory Update for AFM13

Retrieved on: 
Monday, January 9, 2023
IND, NSCLC, PTCL, Large-cell lung carcinoma, CTAS, AML, Stomach, Colorectal cancer, Acute myeloid leukemia, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Trial of the century, Society, Neck, FDA, Macrophage, Immunotherapy, Infrared spectroscopy correlation table, Partnership, Cancer, NK, HL, Food, Patient, Society for Immunotherapy of Cancer, Genentech, Hodgkin lymphoma, EGFR, Roivant Sciences, CTA, SITC, PD-1, CD123, Head, Renal cell carcinoma, Pharmaceutical industry, Affimer

“We believe there is significant unmet need to help patients in these difficult cancer indications with limited treatment options and continue to make progress across our pipeline.

Key Points: 
  • “We believe there is significant unmet need to help patients in these difficult cancer indications with limited treatment options and continue to make progress across our pipeline.
  • Affimed expects to report data from all three ongoing AFM24 studies at scientific conferences in Q2/Q3 2023.
  • AFM24-101: Affimed continues to enroll patients in the expansion phase of the AFM24 monotherapy study at the RP2D.
  • Affimed is eligible for additional proceeds including pre-clinical milestones as well as milestones based on early regulatory achievements.

Roivant Announces Statistically Significant and Clinically Meaningful Results from the Induction Period of TUSCANY-2, a Large Global Phase 2b Study of Subcutaneous RVT-3101 for the Treatment of Ulcerative Colitis in Both the Overall and the Biomarker Posi

Retrieved on: 
Wednesday, January 4, 2023
Precision medicine, Pharmacokinetics, Patient, Mayo, Safety, Webcast, Ulcerative colitis, Pharmaceutical industry, Medical imaging, Fine chemical, High-performance plastics, Roivant Sciences

RVT-3101 will progress into registrational studies as a potential best-in-class and first-in-class subcutaneous therapy in ulcerative colitis.

Key Points: 
  • RVT-3101 will progress into registrational studies as a potential best-in-class and first-in-class subcutaneous therapy in ulcerative colitis.
  • TUSCANY-2 is a large, global, randomized, double-blind, placebo-controlled dose-ranging Phase 2b study to investigate the efficacy, safety, and pharmacokinetics of RVT-3101 in 245 adult participants with moderate to severe ulcerative colitis.
  • During the induction period, patients were treated monthly with subcutaneous RVT-3101 at 50 mg, 150 mg, and 450 mg without a loading dose required.
  • “TUSCANY-2 is among the largest and most robust Phase 2b studies ever conducted in ulcerative colitis.

CHARM Therapeutics Strengthens Leadership Team with Key Appointments to Support Drug Discovery and Development Capability

Retrieved on: 
Wednesday, January 4, 2023
Biomedicine, Hoffmann-La Roche, Khosla Ventures, Stanford University, D, Machine learning, Roivant Sciences, Agios Pharmaceuticals, Pfizer, Doctor of Philosophy, Drug discovery, Head, Research, General Catalyst, Publication, Biology, Master of Science, Medicine, The Tumor, University of Minnesota College of Food, Agricultural and Natural Resource Sciences, Intelligence, AMAG Pharmaceuticals, ARIAD Pharmaceuticals, 3D, Therapy, Drug development, Vertex, Deep learning, GSK, Toxicology, University, Family, Cancer Research UK, Cell, Senior, Weill Cornell Graduate School of Medical Sciences, Pharmacokinetics, Merck & Co., MBA, Data management, Moscow State University, Immersion, DPU, Medical device, Pharmaceutical industry, Management, Crystallography, Science, Health care, Economics, Pharmacology, AI, Nature

LONDON – 4 January 2023 -- CHARM Therapeutics (“CHARM”, “The Company”), a 3D deep-learning research Company discovering and developing transformational medicines, today announces the expansion of its leadership team with a series of key appointments to strengthen its drug discovery and development, as well as operational management capabilities.

Key Points: 
  • Enhanced leadership team brings strong AI and drug discovery expertise and experience, reinforcing CHARM Therapeutics’ existing R&D capabilities
    LONDON – 4 January 2023 -- CHARM Therapeutics (“CHARM”, “The Company”), a 3D deep-learning research Company discovering and developing transformational medicines, today announces the expansion of its leadership team with a series of key appointments to strengthen its drug discovery and development, as well as operational management capabilities.
  • These appointments will support CHARM as it builds out of its research and development function to advance discoveries driven by its proprietary 3D deep-learning engine towards development.
  • CHARM Therapeutics raised $50 million in a Series A financing round announced in 2022, led by F-Prime Capital and OrbiMed, with General Catalyst and Khosla Ventures.
  • Gary D. Glick Ph.D., Executive Chair of CHARM Therapeutics, commented: “The exceptional people joining CHARM bring the perfect combination of skills, from immersion in AI, oncology and translational research to long experience in organizational leadership.

Lyell Immunopharma Appoints Lynn Seely, MD as President and Chief Executive Officer

Retrieved on: 
Thursday, December 15, 2022
Woman, Roivant Sciences, ORGOVYX, SAN, Endometriosis, Hospital, Marketing, University of California, San Diego Performance-Based Skills Assessment, Science, Prostate, Faculty, Medivation, Toxic shock syndrome, Neoplasm, Endocrinology, MD, Yale New Haven Hospital, Internal medicine, History, University, COVID-19, Uterine fibroid, Patient, Metabolism, Management, Pharmaceutical industry, Lyell
Key Points: 

    Bolt Biotherapeutics Appoints Laura Berner to Board of Directors

    Retrieved on: 
    Wednesday, December 14, 2022
    Ropes & Gray, Estradiol, Office of the General Counsel for the Department of the Treasury, Roivant Sciences, Annual report, Stanford Law School, Harvard University, Security (finance), Business, Research Park at the University of Illinois Urbana-Champaign, Macrophage, Safety, Cancer, Rope, Doctor of Philosophy, Norethisterone, Bolt, Genentech, Immune stimulating antibody conjugate, ISAC, Bryn Mawr College, MBA, Research, Nivolumab, IND, General counsel, Biology, University, Patient, Business development, Management, Pharmaceutical industry

    REDWOOD CITY, Calif., Dec. 14, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced the appointment of Laura Berner to its Board of Directors effective Dec. 14, 2022.

    Key Points: 
    • REDWOOD CITY, Calif., Dec. 14, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced the appointment of Laura Berner to its Board of Directors effective Dec. 14, 2022.
    • “Laura is an accomplished biopharmaceutical executive with impressive corporate leadership, operations, and business development experience,” said Randall Schatzman, Ph.D., Chief Executive Officer of Bolt Biotherapeutics.
    • Bolt Biotherapeutics’ pipeline candidates are built on the Company’s deep expertise in myeloid biology and cancer drug development.
    • Bolt Biotherapeutics’ pipeline includes BDC-1001, a HER2-targeting Boltbody Immune-stimulating Antibody Conjugate (ISAC), BDC-3042, a myeloid-modulating antibody, and multiple Boltbody ISAC collaboration programs.

    SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MMX, OFIX, MYOV, PEBO

    Retrieved on: 
    Sunday, December 11, 2022
    Roivant Sciences, NYSE, Advertising, Sale, Fraud, Security (finance), MaveriX

    If you are a Maverix shareholder, click here to learn more about your rights and options .

    Key Points: 
    • If you are a Maverix shareholder, click here to learn more about your rights and options .
    • If you are an Orthofix shareholder, click here to learn more about your rights and options .
    • Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected] .
    • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.